Add to ORKGRadionuclide bone metastases therapy is a major achievement of nuclear medicine. Development of less radiotoxic and more effective radiopharmaceuticals is therefore a challenge for radiopharmacists and industry. This paper reviews the application of rhenium-188 HEDP as a reactor- or generator-produced nuclide for bone metastases therapy
Radionuclide therapy has been an integral part of systemic treatment of patients with advanced and d...
Hendrikse, N.H. [Promotor]Heine, R. ter [Copromotor]Klerk, J.M.H. de [Copromotor]Bloemendal, H.J. [C...
Bone seeking radiopharmaceuticals are indicated in cancer patients with multiple painful skeletal me...
Systemic use of radiopharmaceuticals is a recognized alternative method for the treatment of pain in...
Rhenium-188-hydroxyethylidine diphosphonate(188Re-HEDP) is a novel and attractive radiopharmaceutica...
In this report the authors describe the use of an effective method for concentration of the rhenium-...
AIM: Rhenium-188-HEDP ((188)Re-HEDP) is an effective radiopharmaceutical for the palliative treatmen...
Patients with primary breast, prostate and lung cancer have a high frequency of bone metastases, ran...
In recent decades, the use of alpha; pure beta; or beta/gamma emitters in oncology, endocrinology, a...
Rhenium-188 (Re-188) is a high energy beta-emitting radioisotope with a short 16.9 h physical half-l...
Although established clinical utility is of key importance in choosing agents for radionuclide thera...
188Re Zoledronic acid (188Re-ZA) is new radiopharmaceutical which may have advantages over other bon...
After a lull in development of new chemistry for rhenium-188 and technetium-99m since 2000, there ha...
Bone-seeking radiopharmaceuticals are frequently used as diagnostic agents in nuclear medicine, beca...
By virtue of the rapid development of nuclear medicine technologies, pharmacoeconomics shall occupy ...
Radionuclide therapy has been an integral part of systemic treatment of patients with advanced and d...
Hendrikse, N.H. [Promotor]Heine, R. ter [Copromotor]Klerk, J.M.H. de [Copromotor]Bloemendal, H.J. [C...
Bone seeking radiopharmaceuticals are indicated in cancer patients with multiple painful skeletal me...
Systemic use of radiopharmaceuticals is a recognized alternative method for the treatment of pain in...
Rhenium-188-hydroxyethylidine diphosphonate(188Re-HEDP) is a novel and attractive radiopharmaceutica...
In this report the authors describe the use of an effective method for concentration of the rhenium-...
AIM: Rhenium-188-HEDP ((188)Re-HEDP) is an effective radiopharmaceutical for the palliative treatmen...
Patients with primary breast, prostate and lung cancer have a high frequency of bone metastases, ran...
In recent decades, the use of alpha; pure beta; or beta/gamma emitters in oncology, endocrinology, a...
Rhenium-188 (Re-188) is a high energy beta-emitting radioisotope with a short 16.9 h physical half-l...
Although established clinical utility is of key importance in choosing agents for radionuclide thera...
188Re Zoledronic acid (188Re-ZA) is new radiopharmaceutical which may have advantages over other bon...
After a lull in development of new chemistry for rhenium-188 and technetium-99m since 2000, there ha...
Bone-seeking radiopharmaceuticals are frequently used as diagnostic agents in nuclear medicine, beca...
By virtue of the rapid development of nuclear medicine technologies, pharmacoeconomics shall occupy ...
Radionuclide therapy has been an integral part of systemic treatment of patients with advanced and d...
Hendrikse, N.H. [Promotor]Heine, R. ter [Copromotor]Klerk, J.M.H. de [Copromotor]Bloemendal, H.J. [C...
Bone seeking radiopharmaceuticals are indicated in cancer patients with multiple painful skeletal me...